Loading organizations...
Zymvol Biomodeling specializes in designing and optimizing custom enzymes. Leveraging advanced bioinformatics, molecular modeling, and artificial intelligence, the biotech firm develops tailor-made biocatalysts for specific industrial applications. This computational approach accelerates innovation in biocatalysis by predicting and enhancing enzyme performance, streamlining chemical processes. Zymvol's core offering is a platform generating enzymes with precise functionalities.
Maria Fátima Lucas founded Zymvol Biomodeling in 2017, driven by the insight that computational modeling could revolutionize enzyme industrial use. As CEO, Lucas established the company to apply sophisticated in-silico methods. Her expertise provided the conviction that digital tools could overcome traditional bottlenecks in enzyme discovery and engineering, enabling rapid, precise development of novel biocatalytic solutions.
The company serves industrial clients in chemical, pharmaceutical, and manufacturing sectors, providing custom enzymes for sustainable production. Zymvol's solutions facilitate green chemistry adoption. Its long-term vision is to democratize access to tailored enzymes, positioning green chemistry as the global standard and fostering an environmentally sound future for industrial synthesis.
Zymvol Biomodeling has raised $5.2M across 3 funding rounds.
Zymvol Biomodeling has raised $5.2M in total across 3 funding rounds.
Zymvol Biomodeling has raised $5.2M in total across 3 funding rounds.
Zymvol Biomodeling's investors include Faber, Austin Walne, Elkstone, LGF, Pareto Holdings.
Zymvol Biomodeling is a Barcelona-based biotech company founded in 2017 that designs and discovers industrial enzymes using an AI-Physics hybrid approach combined with molecular modeling and bioinformatics.[1][2][3] It serves R&D managers in diverse industries by accelerating the shift from traditional chemical processes to sustainable biocatalytic ones, solving problems like lengthy trial-and-error enzyme engineering, low yields, and overlooked opportunities through rapid in silico screening that reduces millions of leads to top performers.[2][4] The company has demonstrated growth momentum, including a €3 million seed funding round in February 2025 led by Faber and Elaia Partners, building on its pioneering work since 2017 to democratize green chemistry.[5][7]
Zymvol Biomodeling was established in 2017 in Barcelona, Spain, by a team of scientists and entrepreneurs with deep expertise in enzyme development and biomanufacturing.[1][2][3] Key founders include a scientist-entrepreneur with over 20 years in computer-guided enzyme development (2020 EU Women Innovators prize recipient), the former Head of Biotech at Solvay with 20+ years delivering 14 molecules to market and managing $120M projects, and experts from institutions like Universitat Autònoma de Barcelona (UAB), Barcelona Supercomputing Center, and University of Padova.[3] The idea emerged from leveraging bioinformatics, molecular modeling, and AI to streamline enzyme innovation, addressing inefficiencies in traditional directed evolution methods that plateau after multiple rounds.[2] Early traction came from in-house platform development and partnerships with leading biotechs, evolving into cloud-based simulations for biocatalytic solutions.[6]
Zymvol rides the wave of sustainable biotech and green chemistry, where biocatalysis replaces energy-intensive chemical processes amid rising regulatory pressures for eco-friendly manufacturing and net-zero goals.[1][2] Timing is ideal post-2025 funding, as AI advancements in protein design (e.g., LLMs for enzymes) converge with industrial demands for circular economy solutions in sectors like materials, pharma, and manufacturing.[3][5] Market forces favoring Zymvol include EU innovation grants, corporate sustainability mandates, and the shift to computational biology, amplified by its Barcelona hub in Europe's biotech ecosystem.[1][5] It influences the landscape by democratizing enzyme tech, enabling faster industry transitions, and fostering collaborations that scale biocatalytic impact globally.[2][6]
Zymvol is poised for expansion with its €3M seed fueling platform scaling and industry partnerships, targeting broader biocatalysis adoption amid AI-driven protein engineering trends.[5][7] Expect growth in high-value applications like novel materials and therapeutics, shaped by advancing AI models and regulatory tailwinds for green tech. Its influence could evolve from niche innovator to ecosystem enabler, powering sustainable R&D as chemical giants pivot—reinforcing its mission to make green chemistry the default since day one.[2][3]
Zymvol Biomodeling has raised $5.2M across 3 funding rounds. Most recently, it raised $3.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $3.0M Seed | Faber | Austin Walne, Elkstone, LGF, Pareto Holdings |
| Jan 17, 2024 | $810K Debt | ||
| Feb 21, 2023 | $1.4M Seed |